In individuals with CKD and/or chronic heart failure receiving RAAS blockers, predictors of recurrent hyperkalemia within 6 months of the first episode include initial hyperkalemia with a potassium (K) level of 5.6 mmol/L, an eGFR of 30%, follow-up testing should be performed
Originally developed to treat type 2 diabetes, these medications have become widely used for weight loss and many people of reproductive age are now taking them
Comment ORYGN below and I'll send you the ingredient overview including the research references
Several clinical trials have also shown that GLP-1s can reduce an inflammation marker in the bloodbut its still unclear how much of that improvement is the result of weight loss or an independent effect of the drugs
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
Buyer Takeaway: GI side effects are common, especially early in treatment, and typically manageable
